Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

Guardant Health (GH) reported $201.81 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 30.2%. EPS of -$0.62 for the same period compares to -$1.58 a year ago.The reported revenue represents a surprise of +0.98% over the Zacks Consensus Estimate of $199.86 million. With the consensus EPS estimate being -$0.50, the EPS surprise was -24.00%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total tests performed (clinical & biopharmaceutical customers): 68,350 compared to the 55,415 average estimate based on three analysts. Revenue- Development services and other: $17.23 million versus $13.14 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +33.9% change. Revenue- Precision oncology testing: $184.59 million compared to the $171.76 million average estimate based on five analysts. The reported number represents a change of +29.8% year over year. View all Key Company Metrics for Guardant Health here>>>Shares of Guardant Health have returned +3.8% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Guardant Health, Inc. (GH): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks